The effect of denosumab in breast cancer patients receiving adjuvant aromatase inhibitors: 36-month results
ConclusionTwice-yearly administration of denosumab to the breast cancer patients treated with adjuvant AI, regardless of the skeletal site, resulted in consistent increases in BMD without severe adverse events at 36 months.
Source: Journal of Bone and Mineral Metabolism - Category: Orthopaedics Source Type: research
More News: Breast Cancer | Calcium | Cancer | Cancer & Oncology | Clinical Trials | Orthopaedics | Study | Vitamin D | Vitamins | Xgeva